about
A Perspective of Immunotherapy for Prostate CancerA primer on tumour immunology and prostate cancer immunotherapyMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyImmunotherapy for prostate cancer: recent developments and future challengesFrom bench to bedside: immunotherapy for prostate cancerSipuleucel-T (Provenge®) for castration-resistant prostate cancerAdvances in the understanding of cancer immunotherapyTherapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesImmunotherapy for brain cancer: recent progress and future promiseRapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based VaccinePrognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewConcepts of immunotherapy for gliomaRapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligationWhole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Cancer immunotherapy: sipuleucel-T and beyond.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaImmunotherapy for the treatment of prostate cancer.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayEvolving Personalized Therapy for Castration-Resistant Prostate Cancer.Reciprocal complementation of the tumoricidal effects of radiation and natural killer cellsTherapeutic cancer vaccines: are we there yet?CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.Prostate-specific membrane antigen-based therapeutics.A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatmentIs bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?Oncoantigens for an immune prevention of cancer.Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsProstate cancer immunotherapy.Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Development of PROSTVAC immunotherapy in prostate cancer.
P2860
Q26741277-ED23E19C-8646-44E3-95CE-EB7CC29CF324Q26765697-439B8015-DCE5-4B5A-AE7E-56C1BBF0C163Q26825053-BD8EBB60-BB8A-4D32-9302-3BCCD991BC19Q26852388-5FFAFD55-A0E2-44C7-AAB1-E74D4EC26F94Q26864390-F837031D-5D95-48DA-9927-F2BD8503C48CQ26991753-4FA2A338-7FD2-4CCD-A8EC-BBB1FE91E587Q27000706-035603A2-4CE3-4B08-9E3E-C30F6BFF623FQ27002342-B7DC33CA-B707-4498-B38D-40709161C64AQ27008070-BFD14DCC-1ED9-43EA-9F29-85420444CF77Q27015881-4F746114-034C-4E63-9531-4C489F1D044EQ27317214-667A69B2-6A8C-4E11-94EA-B3C9AB54A359Q28073742-00F6F355-F4F4-4083-B610-F9AE45C4BBB7Q28083888-D25CB42A-3EEA-4878-8DF6-2AD248E6F94CQ30534663-2B7A9C37-678C-4B04-BB7D-C77AA8792403Q33653836-A0320B78-DD7C-4C58-B21E-645AAD87CC43Q33761755-6C2BE425-4B66-4423-8590-CB7BC57AFDA3Q33801246-7CD7CBE0-97BD-4323-825E-3B8786830C80Q33807632-3A99AAC8-8E43-45CA-A2CE-44EFCF1E5756Q33870670-3124289C-A727-48A5-97A0-6AD8A8046AE8Q33916776-A09EF21C-36E0-4752-A055-B6D113685AA2Q34158070-84E72173-7AA3-45F8-893F-900DE9BE7FEFQ34181954-F7D1E271-7D1C-4EFE-B952-2B3A8487D8FFQ34186928-7BC8D365-56F9-4A02-964D-E08CF6EA7D73Q34321844-42FE053B-66E8-44D3-B077-22652F8C0450Q34406488-B3E75A23-4718-45B8-9913-156974BE27A7Q34444867-70AD7229-82D9-4999-AEE7-2E789E77BF64Q34691562-20C96E6A-5850-45C7-BDC9-95F7C85DF4EDQ34698158-B8906F51-9544-4B78-9541-0CC8E5C624D2Q34786691-E7A524AF-5E3F-4EAD-BECE-9681ED826667Q35077753-9DF3B1C6-B456-461D-8454-3E4F1213FFD7Q35122102-2F30DA2D-EFCC-4EC0-92FA-DE84FB10D284Q35132944-5AF12811-7ADE-4A97-944B-9706F70A19ECQ35172536-786B7C23-FC71-413F-8671-6B70E7597AA9Q35214821-6F3946B8-34BD-4E80-9971-46FE9E43BF80Q35232253-EA9148AE-BCB3-4FA6-8661-59E0658681B6Q35249858-EB7D0157-9656-42EA-A2D5-D5515FB31237Q35687743-18A08763-79E8-44B5-8660-4AD9EE127989Q35688425-E114B528-9CE0-4779-9984-40E4EDDFF66BQ35840314-D9506535-6012-4946-B4F3-C4102CF693A3Q35981733-62D9A43C-8568-46F6-839C-118FB440AF55
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prostate cancer as a model for tumour immunotherapy.
@ast
Prostate cancer as a model for tumour immunotherapy.
@en
Prostate cancer as a model for tumour immunotherapy.
@nl
type
label
Prostate cancer as a model for tumour immunotherapy.
@ast
Prostate cancer as a model for tumour immunotherapy.
@en
Prostate cancer as a model for tumour immunotherapy.
@nl
prefLabel
Prostate cancer as a model for tumour immunotherapy.
@ast
Prostate cancer as a model for tumour immunotherapy.
@en
Prostate cancer as a model for tumour immunotherapy.
@nl
P2860
P356
P1476
Prostate cancer as a model for tumour immunotherapy.
@en
P2093
Charles G Drake
P2860
P304
P356
10.1038/NRI2817
P577
2010-08-01T00:00:00Z